Fri, Feb 27, 2015, 12:19 PM EST - U.S. Markets close in 3 hrs 41 mins


% | $
Quotes you view appear here for quick access.

Omeros Corporation (OMER) Message Board

  • Dooper55 Dooper55 Nov 17, 2009 8:13 AM Flag

    Deutsche Bank Initiates Coverage on Omeros Corp (OMER) with a Buy; Emerging Pharmaceutical Company

    November 17, 2009 7:31 AM EST

    Deutsche Bank initiates coverage on Omeros Corp (Nasdaq: OMER) with a Buy rating and a $15 price target.

    Deutsche analyst says, "Omeros is an emerging pharmaceutical company with a late-stage clinical program based on an innovative approach for improving post-surgical outcomes. We believe that the three PharmacoSurgery candidates—OMS103HP for arthroscopy, OMS302 for ophthalmic surgery, and OMS201 for urology—can potentially garner aggregate peak worldwide sales of $1 billion+. Omeros also has a deep preclinical pipeline of programs targeting large underserved markets...In our opinion, at an inexpensive $160 million valuation (technology valuation of $110 million), Omeros’ stock is very attractively priced, given its late stage PharmacoSurgery product portfolio. In fact, based on expected profits from sales of OMS103HP alone, we derive our 12-month price target of $15 (NPV is $11-12), based on 22x our fully taxed 2013 EPS estimate of $1.15, which we discount at 30%."

    To see more analyst ratings on OMER Click Here.

    Omeros Corporation, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing products on inflammation and disorders of the central nervous system.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
20.8884-0.0416(-0.20%)12:19 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.